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RESULTS: Of 290 abstracts screened, 65 met selection criteria
and were reviewed in detail. The average direct medical costs
associated with chemotherapy-induced AEs ranged from
$8,400–$13,500 for neutropenia hospitalization, $5,300–
$7,500 per thrombocytopenia episode, and $14,500–>$114,000
annually for anemia. Key cost drivers for each AE were: neu-
tropenia—hospital length of stay, antibiotics, growth factors,
and diagnostic tests; thrombocytopenia—platelet transfusions
and major bleeding episodes; anemia—EPO-type drugs and
transfusions. Neutropenia and anemia events in patients with
hematologic malignancies resulted in direct medical costs more
than double compared to solid tumors. Indirect costs were >50%
of the direct costs. CONCLUSIONS: Hematologic AEs from
cancer treatments result in substantial economic burden for
payers, patients, and society. This burden appears particularly
heavy for the hematologic malignancies where chemotherapy-
induced hematologic AEs represent >20% of the overall cost of
treatment. Targeted therapies for hematologic malignancy offer
superior outcomes to chemotherapy with reduced AEs. However,
the hematologic toxicities of these targeted agents vary and may
affect the total cost of treatment of the underlying disease. There-
fore, in addition to treatment outcomes, AEs and the cost of
treating AEs should be taken into consideration when determin-
ing the optimal treatment for patients.
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In Romanian haemophiliacs, because of limited access to 
clotting factor concentrates, surgical interventions are made
especially in case of severe, life-threatening complications.
OBJECTIVE: To realize an economic analysis of orthopedic and
surgical interventions. METHODS: In a seven-year period, 37
haemophiliacs (from 224 haemophilia patients registered and
treated in Haemophilia Centre Timisoara) underwent 54 surgi-
cal and orthopedic interventions. We evaluated: direct medical
costs (therapy and hospitalization costs) of these interventions,
direct non-medical costs (home-hospital travel costs), indirect
costs (morbidity costs; loss of income of family members who
forfeit paid employment for haemophiliac home care; average
number of days off at school or work), treatment compliance.
Data were obtained from patients’ medical charts and from 
questionnaires administered to patients. RESULTS: Therapy
costs represented 91.14% of direct medical costs (85.8% 
in haemophilia A without high-titer inhibitors, 95.34% in
haemophilia A with high-titer inhibitors and 92.52% in
haemophilia B patients). Direct non-medical costs represented
high percents of mean patient and family income. Mean monthly
morbidity cost was €97.5 and loss of income of family members
who forfeid employment in order to offer home care for
haemophilia patients was €115.04/month. Average number of
days off at school/work was 72.59/year. CONCLUSIONS: Insuf-
ﬁcient resources lead to severe complications in haemophiliacs,
which can be life-threatening, requiring costly surgical interven-
tions. In the absence of home therapy programs and of Com-
prehensive Haemophilia Care Centers, patients have to travel
long home-hospital distances to a hospital where they can receive
treatment, delaying substitution administration, which is also
responsible for complications appearance. Poor social integra-
tion of patients has a negative impact on personal income, affect-
ing treatment compliance. It is therefore necessary a better
resource allocation for haemophilia treatment, in order to
increase direct medical costs and also to offer a better social pro-
tection of the patients.
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OBJECTIVES: For estimating the cost-effectiveness of interven-
tions to avert blood-transfusions it is important to estimate the
costs of one unit of allogeneic blood. An example of such an
intervention is administration of erythropoietin. Objective of this
study was estimating the costs per unit of erythrocytes in The
Netherlands from a societal perspective. METHODS: For the
estimation of the costs we followed the path from donor to
patient. In this path 6 steps were elaborated: donation, produc-
tion, transport, storage and preparation, administration and the
consequences of administration. In these different steps the cost-
consequences were estimated. RESULTS: Although not all cost-
factors could yet be identiﬁed, the cost-estimate is €240, for a
unit of erythrocytes. The indirect costs are responsible for
approximately 3% of the unit costs. The production and trans-
port part by the Dutch blood banks is responsible for the major-
ity of the costs. CONCLUSIONS: Internationally cost-estimates
vary widely. Cost-estimates for the United States, UK, Sweden
and Canada vary from approximately €130 to €930. For The
Netherlands we estimated the unit costs for a unit of erythro-
cytes at €240 from a societal perspective.
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OBJECTIVE: Patients with β-Thalassemia Major (TM) require
life-long blood transfusions and, to avoid iron overload, Iron
Chelation Treatment (ICT), based on 8–12 hour infusions of
Deferoxamine (DFO) for 5–7 days/week, and/or Deferiprone
(L1) orally administered. ICT regimen often causes low satisfac-
tion and low compliance, with potentially negative consequences
on patients’ health, wellbeing and costs. Aims: to investigate
direct costs of treatment in TM patients. Costs were estimated
from the societal perspective, using tariffs or prices applied in
2006. METHODS: The Italian-THAlassemia-Cost-&-Out-
comes-Assessment (ITHACA) was a naturalistic multicentre
study conducted to evaluate costs, quality of life, compliance and
treatment satisfaction in TM patients undergoing ICT. Patients
of any age, on ICT for at least 3 years, were sequentially enrolled
at 8 Italian Thalassemia Care Centers. Data on direct costs are
referred to a retrospective median observational period of 11.7
